Login / Signup

Waldenström macroglobulinemia and relationship to immune deficiency.

Anthony LevyStéphanie GuidezCéline DebiaisIsabelle PrincetSabrina BouyerElodie DindinaudVincent DelwailThomas SystchenkoNiels MoyaCécile GruchetFlorence SabirouArthur BobinHélène GardeneyLaly NsialaLaura CaillyGaëlle OlivierCarine MotardEmmanuel FleckAnne CorbyChristophe RoulGuillaume DenisCéline DievalXavier LeleuCécile Tomowiak
Published in: Leukemia & lymphoma (2021)
Primary or secondary immune deficiency (ID) is a risk factor, although rare, to develop Waldenström macroglobulinemia (WM). We aimed to better understand the incidence of this occurrence in the real-life and the outcome of either entity. We conducted a review of 194 WM in the Poitou-Charentes registry and identified 7 (3.6%) with a prior history of ID. Across the 7 WM with ID, 4 progressed to active WM disease and required treatment for WM with a median time between WM diagnosis and the first treatment of 1.5 years (range 0-3). The median time from ID to WM occurrence was 8 years (1-18). WM could develop from ID, although a rare event. Our first action was to systematically decrease immunosuppression with long-term control of ID. Half of indolent WM remained indolent despite ID and for remaining WM none appeared of poor risk WM.
Keyphrases
  • risk factors
  • risk assessment
  • combination therapy